Tafamidis Reduced the Decline in Health-Related Quality of Life in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2019.07.024
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2019
Authors
Publisher
Elsevier BV